Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 17/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 17/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.58 |
| ▸ | CHRNA1 | P02708 | 16/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 16/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.58 |
| ▸ | CHRNG | P07510 | 15/20 | 0.58 |
| ▸ | CHRND | Q07001 | 15/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manifaxine SCHEMBL2954001 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL7775056 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL2633826 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9696551 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL1820725 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9696258 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9696265 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9695101 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9697408 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 | |
| Manifaxine SCHEMBL9696223 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5104870-A | Psychological disorders | BURROUGHS WELLCOME CO. (US) | 1992-04-14 | — | — | US | claimed |
| EP-0426416-A1 | Novel morpholinol compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-05-08 | — | — | EP | claimed |
| EP-1968603-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | Algebra Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079470-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1117407-A1 | ORAL DOSAGE FORMULATIONS COMPRISING (2S, 3S,5R)-2-(3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL AND AN EFFECTIVE STABILIZING AMOUNT OF ALGINIC ACID | GLAXO GROUP LIMITED (GB) | 2001-07-25 | — | — | EP | disclosed |